risperidone has been researched along with Depression in 84 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms [Hamilton Depression Rating Scale (HAM-D) score≥20 and a HAM-D item 1 score≥2]." | 9.20 | Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. ( Di Fiorino, M; Kasper, S; Montagnani, G; Trespi, G, 2015) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 9.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 9.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 9.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 9.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 9.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 9.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 9.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 9.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| " The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia." | 9.10 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. ( Amico, E; Evins, AE; Goff, DC; Posever, TA; Toker, R, 2002) |
| "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 7.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| " The atypical antipsychotic risperidone and the selective serotonin (5-HT)(2) antagonist ritanserin normalized the depression-like behavior in PACAP-/- mice." | 7.75 | Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. ( Baba, A; Guo, X; Hashimoto, H; Hashimoto, R; Hatanaka, M; Morita, Y; Nagai, K; Shintani, N; Takeda, M; Tanaka, K; Tanida, M; Yamamoto, A, 2009) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 7.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 7.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| " The typical neuroleptics, chlorpromazine and haloperidol, led to prolonged depression of responding lasting at least 4 h, whereas response rates after similarly effective doses of the atypical agents, clozapine and risperidone, recovered to control levels in the same period." | 7.70 | Rapid recovery of self-stimulation responding from depression by clozapine is prevented by the alpha 2-adrenoceptor agonist, clonidine. ( Grottick, AJ; Herberg, LJ; Montgomery, AM, 1999) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 5.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| "The present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms [Hamilton Depression Rating Scale (HAM-D) score≥20 and a HAM-D item 1 score≥2]." | 5.20 | Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. ( Di Fiorino, M; Kasper, S; Montagnani, G; Trespi, G, 2015) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 5.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 5.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 5.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "The results of this post hoc analysis of affective symptoms of DBDs using data from a previously published randomized, double-blind clinical comparison of risperidone and placebo in the treatment of children with DBDs and subaverage intelligence suggest that risperidone was effective in treating the factors of explosive irritability; agitated, expansive, grandiose; and depression." | 5.12 | Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. ( Biederman, J; Faraone, SV; Mick, E; Pandina, G; Spencer, T; Wozniak, J, 2006) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 5.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 5.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 5.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 5.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 5.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| " The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia." | 5.10 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. ( Amico, E; Evins, AE; Goff, DC; Posever, TA; Toker, R, 2002) |
| " Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression." | 4.90 | Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014) |
| "Treating acute mania with atypicals is associated to 42% less risk of switch to depression than with haloperidol." | 4.89 | Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013) |
| "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| "Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders." | 3.83 | The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. ( Kaminska, K; Rogoz, Z, 2016) |
| "Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression." | 3.78 | Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 3.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| " The atypical antipsychotic risperidone and the selective serotonin (5-HT)(2) antagonist ritanserin normalized the depression-like behavior in PACAP-/- mice." | 3.75 | Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. ( Baba, A; Guo, X; Hashimoto, H; Hashimoto, R; Hatanaka, M; Morita, Y; Nagai, K; Shintani, N; Takeda, M; Tanaka, K; Tanida, M; Yamamoto, A, 2009) |
| "Clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression." | 3.74 | Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. ( Dhir, A; Kulkarni, SK, 2008) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 3.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 3.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| " The typical neuroleptics, chlorpromazine and haloperidol, led to prolonged depression of responding lasting at least 4 h, whereas response rates after similarly effective doses of the atypical agents, clozapine and risperidone, recovered to control levels in the same period." | 3.70 | Rapid recovery of self-stimulation responding from depression by clozapine is prevented by the alpha 2-adrenoceptor agonist, clonidine. ( Grottick, AJ; Herberg, LJ; Montgomery, AM, 1999) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "Among patients with military-related PTSD with SRI-resistant symptoms, 6-month treatment with risperidone compared with placebo did not reduce PTSD symptoms." | 2.76 | Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. ( Cramer, JA; Horney, RA; Huang, GD; Jones, KM; Krystal, JH; Rosenheck, RA; Stock, C; Vertrees, JE; Vessicchio, JC, 2011) |
| "Early intervention in autism spectrum disorders (ASDs) appears promising and may represent a window of opportunity for more effective treatment." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 1.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| " These results further support the previous suggestion that the cortical dopamine system plays an important role in the effects of antipsychotic drugs administered in combination with fluvoxamine." | 1.33 | Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. ( Ago, Y; Baba, A; Matsuda, T; Nakamura, S; Sato, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (11.90) | 18.2507 |
| 2000's | 35 (41.67) | 29.6817 |
| 2010's | 36 (42.86) | 24.3611 |
| 2020's | 3 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Scott, F | 1 |
| Hampsey, E | 1 |
| Gnanapragasam, S | 1 |
| Carter, B | 1 |
| Marwood, L | 1 |
| Taylor, RW | 1 |
| Emre, C | 1 |
| Korotkova, L | 1 |
| Martín-Dombrowski, J | 1 |
| Cleare, AJ | 1 |
| Young, AH | 2 |
| Strawbridge, R | 1 |
| Cantù, F | 1 |
| Ciappolino, V | 1 |
| Enrico, P | 1 |
| Moltrasio, C | 1 |
| Delvecchio, G | 1 |
| Brambilla, P | 1 |
| Veraart, JKE | 1 |
| Smith-Apeldoorn, SY | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Kamphuis, J | 1 |
| Schoevers, RA | 1 |
| Touw, DJ | 1 |
| Robinson, DG | 1 |
| Gallego, JA | 1 |
| John, M | 1 |
| Hanna, LA | 1 |
| Zhang, JP | 1 |
| Birnbaum, ML | 1 |
| Greenberg, J | 1 |
| Naraine, M | 1 |
| Peters, BD | 1 |
| McNamara, RK | 1 |
| Malhotra, AK | 1 |
| Szeszko, PR | 1 |
| Elahi, E | 1 |
| Zia, U | 1 |
| Bhutta, OA | 1 |
| Andleeb, S | 1 |
| Smith, RC | 1 |
| Leucht, S | 1 |
| Davis, JM | 1 |
| Frizzell, W | 1 |
| Howard, L | 1 |
| Norris, HC | 1 |
| Chien, J | 1 |
| Roman, A | 1 |
| Kuśmierczyk, J | 1 |
| Klimek, E | 1 |
| Rogóż, Z | 4 |
| Nalepa, I | 1 |
| Kabziński, M | 2 |
| Sadaj, W | 1 |
| Rachwalska, P | 1 |
| Gądek-Michalska, A | 1 |
| Di Fiorino, M | 2 |
| Montagnani, G | 2 |
| Trespi, G | 2 |
| Kasper, S | 2 |
| Laver, B | 1 |
| Diwan, M | 1 |
| Nobrega, JN | 1 |
| Hamani, C | 1 |
| Usall, J | 1 |
| López-Carrilero, R | 1 |
| Iniesta, R | 1 |
| Roca, M | 1 |
| Caballero, M | 1 |
| Rodriguez-Jimenez, R | 1 |
| Oliveira, C | 1 |
| Bernardo, M | 1 |
| Corripio, I | 1 |
| Sindreu, SD | 1 |
| González Piqueras, JC | 1 |
| Felipe, AE | 1 |
| Fernandez de Corres, B | 1 |
| Ibáñez, A | 1 |
| Huerta, R | 1 |
| Zeinoddini, A | 1 |
| Ahadi, M | 1 |
| Farokhnia, M | 1 |
| Rezaei, F | 1 |
| Tabrizi, M | 2 |
| Akhondzadeh, S | 2 |
| Taylor, DM | 1 |
| Cornelius, V | 1 |
| Smith, L | 1 |
| Noto, C | 1 |
| Ota, VK | 1 |
| Gouvea, ES | 1 |
| Rizzo, LB | 1 |
| Spindola, LM | 1 |
| Honda, PH | 1 |
| Cordeiro, Q | 1 |
| Belangero, SI | 1 |
| Bressan, RA | 2 |
| Gadelha, A | 1 |
| Maes, M | 1 |
| Brietzke, E | 1 |
| Kim, SW | 2 |
| Jeong, BO | 1 |
| Kim, JM | 2 |
| Shin, IS | 2 |
| Hwang, MY | 1 |
| Paul Amminger, G | 1 |
| Nelson, B | 1 |
| Berk, M | 1 |
| McGorry, P | 1 |
| Yoon, JS | 2 |
| Khodaie-Ardakani, MR | 1 |
| Khosravi, M | 1 |
| Zarinfard, R | 1 |
| Nejati, S | 1 |
| Mohsenian, A | 1 |
| De Santis, M | 1 |
| Lian, J | 1 |
| Huang, XF | 1 |
| Deng, C | 1 |
| Koplewicz, HS | 1 |
| Salpekar, JA | 1 |
| Joshi, PT | 1 |
| Axelson, DA | 1 |
| Reinblatt, SP | 1 |
| Yenokyan, G | 1 |
| Sanyal, A | 1 |
| Walkup, JT | 1 |
| Vitiello, B | 1 |
| Luby, JL | 1 |
| Wagner, KD | 1 |
| Nusrat, N | 1 |
| Riddle, MA | 1 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Morozova, MA | 1 |
| Platova, AI | 1 |
| Baymeeva, NV | 1 |
| Miroshnichenko, II | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Kaminska, K | 1 |
| Pasa, S | 1 |
| Sayhan, MB | 1 |
| Boyraz, T | 1 |
| Urakci, Z | 1 |
| Altintas, A | 1 |
| Dhir, A | 1 |
| Kulkarni, SK | 1 |
| Hashimoto, H | 1 |
| Hashimoto, R | 1 |
| Shintani, N | 1 |
| Tanaka, K | 1 |
| Yamamoto, A | 1 |
| Hatanaka, M | 1 |
| Guo, X | 1 |
| Morita, Y | 1 |
| Tanida, M | 1 |
| Nagai, K | 1 |
| Takeda, M | 1 |
| Baba, A | 2 |
| Yasui-Furukori, N | 1 |
| Saito, M | 1 |
| Nakagami, T | 1 |
| Furukori, H | 1 |
| Suzuki, A | 1 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Caligiuri, MP | 1 |
| Teulings, HL | 1 |
| Dean, CE | 1 |
| Niculescu, AB | 1 |
| Lohr, J | 1 |
| Mowla, A | 1 |
| Dastgheib, SA | 1 |
| Ebrahimi, AA | 1 |
| Pani, A | 1 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Ren, XS | 1 |
| Crivera, C | 1 |
| Sikirica, M | 1 |
| Dirani, R | 1 |
| Qian, S | 1 |
| Kazis, LE | 1 |
| Ortega-Alvaro, A | 1 |
| Aracil-Fernández, A | 1 |
| García-Gutiérrez, MS | 1 |
| Navarrete, F | 1 |
| Manzanares, J | 1 |
| Riedel, M | 2 |
| Mayr, A | 2 |
| Seemüller, F | 2 |
| Maier, W | 2 |
| Klingberg, S | 1 |
| Heuser, I | 2 |
| Klosterkötter, J | 2 |
| Gastpar, M | 2 |
| Schmitt, A | 2 |
| Sauer, H | 1 |
| Schneider, F | 2 |
| Gaebel, W | 2 |
| Jäger, M | 2 |
| Möller, HJ | 3 |
| Schennach-Wolff, R | 1 |
| Krystal, JH | 1 |
| Rosenheck, RA | 2 |
| Cramer, JA | 1 |
| Vessicchio, JC | 1 |
| Jones, KM | 1 |
| Vertrees, JE | 1 |
| Horney, RA | 1 |
| Huang, GD | 1 |
| Stock, C | 1 |
| Kjelby, E | 1 |
| Jørgensen, HA | 1 |
| Kroken, RA | 1 |
| Løberg, EM | 1 |
| Johnsen, E | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Yoshimura, R | 2 |
| Nakamura, J | 2 |
| Gadit, A | 1 |
| Chung, YC | 1 |
| Lee, YH | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Bae, KY | 1 |
| Schennach, R | 1 |
| Musil, R | 1 |
| Klingenberg, S | 1 |
| Schlösser, R | 1 |
| Ohmann, C | 1 |
| Lewitzka, U | 1 |
| Milovancevic, MP | 1 |
| Miletic, V | 1 |
| Deusic, SP | 1 |
| Gajic, SD | 1 |
| Tosevski, DL | 1 |
| Goikolea, JM | 1 |
| Colom, F | 1 |
| Torres, I | 1 |
| Capapey, J | 1 |
| Valentí, M | 1 |
| Undurraga, J | 1 |
| Grande, I | 1 |
| Sanchez-Moreno, J | 1 |
| Vieta, E | 1 |
| Peuskens, J | 1 |
| Puech, A | 1 |
| Sakic, B | 1 |
| Lacosta, S | 1 |
| Denburg, JA | 1 |
| Szechtman, H | 1 |
| Spina, E | 1 |
| Avenoso, A | 1 |
| Scordo, MG | 1 |
| Ancione, M | 1 |
| Madia, A | 1 |
| Gatti, G | 1 |
| Perucca, E | 1 |
| Oosthuizen, P | 1 |
| Emsley, RA | 1 |
| Roberts, MC | 1 |
| Turner, J | 1 |
| Keyter, L | 1 |
| Keyter, N | 1 |
| Torreman, M | 1 |
| Margolese, HC | 1 |
| Annable, L | 1 |
| Dion, Y | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Wöhrle, JC | 1 |
| Weigel, R | 1 |
| Grips, E | 1 |
| Blahak, C | 1 |
| Capelle, HH | 1 |
| Krauss, JK | 1 |
| Philipp, M | 1 |
| Lesch, OM | 1 |
| Schmauss, M | 1 |
| Dose, M | 1 |
| Glaser, T | 1 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 1 |
| Tollefson, GD | 1 |
| Zhang, F | 1 |
| Breier, A | 1 |
| Lane, HY | 1 |
| Lin, CC | 1 |
| Huang, CH | 1 |
| Chang, YC | 1 |
| Hsu, SK | 1 |
| Chang, WH | 1 |
| Slauson, SD | 1 |
| LoVecchio, F | 1 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| Srinivasan, J | 1 |
| McCann, S | 1 |
| Konarski, JZ | 1 |
| Kennedy, SH | 1 |
| Gayubo Moreo, L | 1 |
| Martínez Pastor, CJ | 1 |
| García Recio, A | 1 |
| Gasquet, I | 1 |
| Haro, JM | 1 |
| Novick, D | 1 |
| Edgell, ET | 1 |
| Kennedy, L | 1 |
| Lepine, JP | 1 |
| Fleischhacker, WW | 1 |
| Rabinowitz, J | 1 |
| Kemmler, G | 1 |
| Eerdekens, M | 1 |
| Mehnert, A | 1 |
| Dollfus, S | 1 |
| Olivier, V | 1 |
| Chabot, B | 1 |
| Déal, C | 1 |
| Perrin, E | 1 |
| Goto, M | 1 |
| Kakihara, S | 1 |
| Shinkai, K | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Ueda, N | 1 |
| Rapaport, MH | 1 |
| Gharabawi, GM | 1 |
| Canuso, CM | 1 |
| Mahmoud, RA | 1 |
| Keller, MB | 1 |
| Bossie, CA | 1 |
| Turkoz, I | 2 |
| Lasser, RA | 1 |
| Loescher, A | 1 |
| Bouhours, P | 1 |
| Dunbar, F | 1 |
| Nemeroff, CB | 1 |
| Biederman, J | 1 |
| Mick, E | 1 |
| Faraone, SV | 1 |
| Wozniak, J | 1 |
| Spencer, T | 1 |
| Pandina, G | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Ago, Y | 1 |
| Sato, M | 1 |
| Nakamura, S | 1 |
| Matsuda, T | 1 |
| Gharabawi, G | 1 |
| Bossie, C | 1 |
| Kujawa, M | 1 |
| Mahmoud, R | 1 |
| Simpson, G | 1 |
| Villeneuve, A | 1 |
| Zuddas, A | 1 |
| Pintor, M | 1 |
| Cianchetti, C | 1 |
| Lübbe, R | 1 |
| Frischauf, E | 1 |
| Franz, M | 1 |
| Lis, S | 1 |
| Plüddemann, K | 1 |
| Gallhofer, B | 1 |
| Yee, CM | 1 |
| Nuechterlein, KH | 1 |
| Morris, SE | 1 |
| White, PM | 1 |
| Meares, S | 1 |
| Draper, B | 1 |
| Bakaras, P | 1 |
| Georgoussi, M | 1 |
| Liakos, A | 1 |
| Panagiotis, B | 1 |
| Maria, G | 1 |
| Aris, L | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Keck, PE | 1 |
| Strakowski, SM | 1 |
| McElroy, SL | 1 |
| Montgomery, AM | 1 |
| Grottick, AJ | 1 |
| Herberg, LJ | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Jones, HM | 1 |
| Ell, PJ | 1 |
| Pilowsky, LS | 1 |
| Ismail, M | 1 |
| Lyster, G | 1 |
| Nieman, DH | 1 |
| Koelman, JH | 1 |
| Linszen, DH | 1 |
| Bour, LJ | 1 |
| Dingemans, PM | 1 |
| Ongerboer de Visser, BW | 1 |
| Evins, AE | 1 |
| Amico, E | 1 |
| Posever, TA | 1 |
| Toker, R | 1 |
| Goff, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment[NCT01786239] | 50 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study[NCT00640562] | Phase 3 | 216 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia[NCT01300364] | Phase 4 | 249 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder[NCT00099983] | Phase 2 | 296 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.[NCT00932529] | Phase 4 | 226 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial[NCT00827840] | Phase 4 | 58 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms. (NCT01786239)
Timeframe: 16 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline BPRS Score | Week 16 BPRS Score | |
| Omega-3 Capsules & Risperidone | 41.64 | 22.5868 |
| Placebo & Risperidone | 42.38 | 27.2235 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | -1.50 |
| Risperidone | -1.04 |
Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment. (NCT00640562)
Timeframe: 12 week
| Intervention | Kg/m^2 (Mean) |
|---|---|
| Seroquel XR | 29.07 |
| Risperidone | 28.80 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12week: descriptive statistic of CGI by visit and treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Seroquel XR | 91 |
| Risperidone | 88 |
"Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.~The SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40~Change from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments." (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 2.74 |
| Risperidone | 3.88 |
"The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.~CDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.~The sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression." (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 7.31 |
| Risperidone | 5.53 |
These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 86.38 |
| Risperidone | 76.64 |
21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Mean) |
|---|---|
| Seroquel XR | -29.83 |
| Risperidone | -23.02 |
30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 102.26 |
| Risperidone | 100.51 |
Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit (NCT00640562)
Timeframe: 12 week from screening visit to last visit
| Intervention | KG (Least Squares Mean) |
|---|---|
| Seroquel XR | 61.20 |
| Risperidone | 90.80 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: Change of drug use from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 14 |
| Risperidone | 17 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: 12 week from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 12 |
| Risperidone | 11 |
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
The primary outcome measure for this study was the total score on the 34-item Clinician-Administered PTSD Scale (CAPS). This study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. Total score range for the CAPS is 0-136 with higher values representing a worse outcome. This study was powered initially to detect a 9-point difference between the treatment groups in the CAPS change score. (NCT00099983)
Timeframe: 24 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Risperidone | -16.3 |
| Sugar Pill | -12.5 |
11 reviews available for risperidone and Depression
| Article | Year |
|---|---|
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression.
Topics: Adult; Aripiprazole; Depression; Depressive Disorder, Major; Humans; Ketamine; Risperidone | 2023 |
Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression.
Topics: Antipsychotic Agents; Benzodiazepines; Depression; Humans; Olanzapine; Quetiapine Fumarate; Risperid | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles; | 2019 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2014 |
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord | 2013 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
Pathophysiology and treatment of negative symptoms.
Topics: Antipsychotic Agents; Brain; Depression; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piper | 1994 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
27 trials available for risperidone and Depression
| Article | Year |
|---|---|
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Bipolar Disorder; Brief Psychiatric Rating Scale; | 2019 |
Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depression; Dibenzothiazepines; Dose-Respo | 2014 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double- | 2014 |
L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Female; Follow-Up Stu | 2014 |
Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depression; Dibenzothiazepines; Female; Hu | 2015 |
A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Humans; Mal | 2015 |
Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depression; Female; Hum | 2015 |
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up St | 2012 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzodiazepines; Depression; Dibenzothiazepines; Fem | 2011 |
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depressio | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Double-Blind Metho | 2002 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
[Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Topics: Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Dyskinesia, Drug-Induced; Fl | 2003 |
Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Depression; Female; Gen | 2004 |
The antidepressant effects of risperidone and olanzapine in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body W | 2004 |
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Dep | 2005 |
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depression; Double-Blind Method; Fem | 2005 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Res | 2006 |
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chi-Square Distribution; Citalopra | 2006 |
Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Depre | 2006 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Awareness; Cognition Disorders; Delayed-Act | 2007 |
P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Anxiety; Attention; Cognition; Depression; Evoked | 1998 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Topics: Adult; Antipsychotic Agents; Cycloserine; Depression; Dose-Response Relationship, Drug; Double-Blind | 2002 |
46 other studies available for risperidone and Depression
| Article | Year |
|---|---|
Extrapyramidal symptoms resulting from risperidone use in a four year old child: A case report.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child, Preschool; Depression; Female; Humans; Risperid | 2018 |
Homicidal Ideation and Individuals on the Autism Spectrum.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder; Bup | 2019 |
Effects of co-administration of fluoxetine and risperidone on properties of peritoneal and pleural macrophages in rats subjected to the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arginase; Behavior, Animal; | 2012 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A | 2012 |
Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats.
Topics: Animals; Behavior, Animal; Buspirone; Deep Brain Stimulation; Depression; Dopamine Antagonists; Gyru | 2014 |
Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytokines; Depression; Female; Flow Cytometry; Humans; Male | 2014 |
Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depression; Female; Humans; Male; Middle Aged; Obsessive-C | 2015 |
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines | 2016 |
From the Editor-in-Chief's Desk.
Topics: Bipolar Disorder; Depression; Gynecomastia; Humans; Mental Processes; Quetiapine Fumarate; Reward; R | 2015 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Cit | 2016 |
A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone.
Topics: Antipsychotic Agents; Depression; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Rispe | 2008 |
Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2008 |
Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone.
Topics: Animals; Antipsychotic Agents; Body Temperature; Circadian Rhythm; Corticosterone; Depression; Male; | 2009 |
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety; Cognition; Data Interpretation, Statistical; Depression; | 2010 |
Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Topics: Adult; Age of Onset; Antipsychotic Agents; Confidence Intervals; Depression; Drug Monitoring; Dyskin | 2009 |
Nasal bleeding associated with fluoxetine and risperidone interaction: a case report.
Topics: Depression; Drug Interactions; Epistaxis; Fluoxetine; Follow-Up Studies; Humans; Male; Risperidone; | 2009 |
Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Topics: Adult; Aged; Alcoholism; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Depression; | 2011 |
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Avoidance Learni | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depression; Drug Synergism; Drug Therapy, Combination; Immobilizatio | 2011 |
[Effects of smoking and caffeine on pharmacological treatment for patients with schizophrenia and depression].
Topics: Caffeine; Depression; Drug Interactions; Fluvoxamine; Humans; Risperidone; Schizophrenia; Smoking | 2011 |
Risperidone associated tardive dyskinesia--a less common phenomenon.
Topics: Anxiety; Depression; Humans; Male; Middle Aged; Movement Disorders; Risperidone; Serotonin Antagonis | 2011 |
Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Child; Depression; Diazepam; Female; Humans; Lupus Erythe | 2013 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence.
Topics: Aging; Animals; Antibodies, Antinuclear; Autoimmune Diseases; Behavior, Animal; Brain; Brain Chemist | 2002 |
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
Topics: Adult; Antipsychotic Agents; Depression; Drug Interactions; Drug Therapy, Combination; Female; Fluox | 2002 |
Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Depressive Disorder, Major; Dose-Response | 2002 |
Risperidone-responsive segmental dystonia and pallidal deep brain stimulation.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Depression; Dopamine Antagoni | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Risperidone-induced priapism with rechallenge.
Topics: Adult; Antipsychotic Agents; Depression; Emergency Medicine; Humans; Male; Paranoid Personality Diso | 2004 |
Mesial temporal sclerosis and psychiatric symptoms: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Brain; Depression; Diagnosis, Differential; Electroence | 2004 |
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Demography; Depr | 2005 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Depression; Drug Interactions; Drug Therapy, Combinati | 2006 |
Risperidone for negative symptoms.
Topics: Adolescent; Antipsychotic Agents; Child; Depression; Female; Humans; Psychiatric Status Rating Scale | 1996 |
[Remission of schizophrenic psychosis with negative symptoms with risperidone].
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; Depression; Hallucinations; Humans; Male; Ps | 1996 |
Drug therapy in autism.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Autistic Disorder; Buspirone; Child; Depression; Drug The | 1997 |
Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cross-Sectiona | 1997 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; H | 1999 |
Development of obsessive and depressive symptoms during risperidone treatment.
Topics: Adult; Antipsychotic Agents; Depression; Humans; Male; Obsessive-Compulsive Disorder; Risperidone | 1999 |
Rapid recovery of self-stimulation responding from depression by clozapine is prevented by the alpha 2-adrenoceptor agonist, clonidine.
Topics: Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Clonidine; Clozapine; Depression; Dose-Res | 1999 |
Dopamine D(2) receptor blockade in schizophrenia.
Topics: Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Depression; Dopamine D2 Receptor A | 2001 |
Treatment of psychotic depression associated with steroid therapy in Churg-Strauss syndrome.
Topics: Adrenal Cortex Hormones; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Churg-Strau | 2002 |
Clinical and neuropsychological correlates of the P300 in schizophrenia.
Topics: Adult; Benzodiazepines; Depression; Event-Related Potentials, P300; Female; Humans; Male; Neuropsych | 2002 |